miR‑508‑3p suppresses the development of ovarian carcinoma by targeting CCNA2 and MMP7

Guo,Fei; Zhang,Kai; Li,Meiyue; Cui,Lei; Liu,Guoyan; Yan,Ye; Tian,Wenyan; Teng,Fei; Zhang,Yanfang; Gao,Chao; Gao,Jinping; Wang,Yingmei; Xue,Fengxia

doi:10.3892/ijo.2020.5055

miR‑508‑3p suppresses the development of ovarian carcinoma by targeting CCNA2 and MMP7

Authors:
- Fei Guo
- Kai Zhang
- Meiyue Li
- Lei Cui
- Guoyan Liu
- Ye Yan
- Wenyan Tian
- Fei Teng
- Yanfang Zhang
- Chao Gao
- Jinping Gao
- Yingmei Wang
- Fengxia Xue
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China, Department of Gynecology and Obstetrics, Tianjin First Central Hospital, Tianjin 300192, P.R. China
Published online on: April 27, 2020 https://doi.org/10.3892/ijo.2020.5055
Pages: 264-276
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is the most lethal gynecological tumor, and the 5‑year survival rate is only ~40%. The poor survival rate is due to cancer diagnosis at an advanced stage, when the tumor has metastasized. A better understanding of the molecular pathogenesis of tumor growth and metastasis is needed to improve patient prognosis. MicroRNAs (miRs) regulate carcinogenesis and development of cancers. However, the role of miR‑508‑3p in ovarian cancer remains largely unknown. Thus, the present study aimed to investigate the possible functions of miR‑508‑3p in the modulation of development of ovarian cancer. The results of the present study demonstrated that miR‑508‑3p mimics inhibited ovarian cancer cell proliferation, migration and invasion. Reporter gene assay results demonstrated that miR‑508‑3p suppressed cancer cell proliferation by directly targeting the 3'‑untranslated region (UTR) of cyclin A2 (CCNA2) and suppressed migration and invasion by directly targeting the 3'‑UTR of matrix metalloproteinase 7 (MMP7). In addition, high CCNA2 and MMP7 expression levels were associated with low miR‑508‑3p expression in ovarian cancer tissues. Furthermore, miR‑508‑3p and CCNA2 were independent predictors for overall survival in patients with ovarian cancer. To the best of our knowledge, this is the first study to demonstrated that miR‑508‑3p suppressed ovarian cancer development by directly targeting CCNA2 and MMP7. The results of this study suggested the potential value of miR‑508‑3p and CCNA2 as prognostic indicators and therapeutics for ovarian cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Nasioudis D, Kahn R, Chapman-Davis E, Frey MK, Caputo TA, Witkin SS and Holcomb K: Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma. Gynecol Oncol. 154:401–404. 2019. View Article : Google Scholar : PubMed/NCBI
4	Rojas V, Hirshfield KM, Ganesan S and Rodriguez-Rodriguez L: Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. Int J Mol Sci. 17:172016. View Article : Google Scholar
5	Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, et al CONCORD Working Group: Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 385:977–1010. 2015. View Article : Google Scholar
6	Zhai Q, Zhou L, Zhao C, Wan J, Yu Z, Guo X, Qin J, Chen J and Lu R: Identification of miR-508-3p and miR-509-3p that are associated with cell invasion and migration and involved in the apoptosis of renal cell carcinoma. Biochem Biophys Res Commun. 419:621–626. 2012. View Article : Google Scholar : PubMed/NCBI
7	Yu X, Zhang X, Bi T, Ding Y, Zhao J, Wang C, Jia T, Han D, Guo G, Wang B, et al: MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. Tumour Biol. 34:3501–3508. 2013. View Article : Google Scholar : PubMed/NCBI
8	Hidaka H, Seki N, Yoshino H, Yamasaki T, Yamada Y, Nohata N, Fuse M, Nakagawa M and Enokida H: Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma. Oncotarget. 3:44–57. 2012. View Article : Google Scholar : PubMed/NCBI
9	Huang T, Kang W, Zhang B, Wu F, Dong Y, Tong JH, Yang W, Zhou Y, Zhang L, Cheng AS, et al: miR-508-3p concordantly silences NFKB1 and RELA to inactivate canonical NF-κB signaling in gastric carcinogenesis. Mol Cancer. 15:92016. View Article : Google Scholar
10	Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S and Matsubara O: Cumulative alterations of p27-related cell-cycle regulators in the development of endometriosis-associated ovarian clear cell adenocarcinoma. Histopathology. 56:740–749. 2010. View Article : Google Scholar : PubMed/NCBI
11	Lee YH, Heo JH, Kim TH, Kang H, Kim G, Kim J, Cho SH and An HJ: Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Int J Gynecol Pathol. 30:205–217. 2011. View Article : Google Scholar : PubMed/NCBI
12	Song N, Liu H, Ma X and Zhang S: Placental growth factor promotes metastases of ovarian cancer through miR-543-regulated MMP7. Cell Physiol Biochem. 37:1104–1112. 2015. View Article : Google Scholar : PubMed/NCBI
13	Yu B, Liu X and Chang H: MicroRNA-143 inhibits colorectal cancer cell proliferation by targeting MMP7. Minerva Med. 108:13–19. 2017.
14	Berek JS, Crum C and Friedlander M: Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 119(Suppl 2): S118–S129. 2012. View Article : Google Scholar : PubMed/NCBI
15	Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, et al: Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 23:186–199. 2013. View Article : Google Scholar : PubMed/NCBI
16	Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, Li X, Gumin J, Zheng H, Hu L, et al: The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest. 123:855–865. 2013.PubMed/NCBI
17	Zarkowska T, U S, Harlow E and Mittnacht S: Monoclonal antibodies specific for underphosphorylated retinoblastoma protein identify a cell cycle regulated phosphorylation site targeted by CDKs. Oncogene. 14:249–254. 1997. View Article : Google Scholar : PubMed/NCBI
18	Wang X, Hu Y, Cui J, Zhou Y and Chen L: Coordinated targeting of MMP-2/MMP-9 by miR-296-3p/FOXCUT exerts tumor-suppressing effects in choroidal malignant melanoma. Mol Cell Biochem. 445:25–33. 2018. View Article : Google Scholar
19	Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, et al: miR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol. 235:25–36. 2015. View Article : Google Scholar
20	Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D, Parker Kerrigan BC, Shmulevich I, Chen K, Sood AK, et al: miR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol. 233:308–318. 2014. View Article : Google Scholar : PubMed/NCBI
21	Sun Y, Guo F, Bagnoli M, Xue FX, Sun BC, Shmulevich I, Mezzanzanica D, Chen KX, Sood AK, Yang D, et al: Key nodes of a microRNA network associated with the integrated mesen-chymal subtype of high-grade serous ovarian cancer. Chin J Cancer. 34:28–40. 2015. View Article : Google Scholar : PubMed/NCBI
22	Lin C, Liu A, Zhu J, Zhang X, Wu G, Ren P, Wu J, Li M, Li J and Song L: miR-508 sustains phosphoinositide signalling and promotes aggressive phenotype of oesophageal squamous cell carcinoma. Nat Commun. 5:46202014. View Article : Google Scholar : PubMed/NCBI
23	Cribier A, Descours B, Valadão AL, Laguette N and Benkirane M: Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1. Cell Rep. 3:1036–1043. 2013. View Article : Google Scholar : PubMed/NCBI
24	Das E, Jana NR and Bhattacharyya NP: MicroRNA-124 targets CCNA2 and regulates cell cycle in STHdh(Q111)/Hdh(Q111) cells. Biochem Biophys Res Commun. 437:217–224. 2013. View Article : Google Scholar : PubMed/NCBI
25	van Olphen SH, Ten Kate FJ, Doukas M, Kastelein F, Steyerberg EW, Stoop HA, Spaander MC, Looijenga LH, Bruno MJ, Biermann K and ProBar-Study Group: value of cyclin A immunohistochemistry for cancer risk stratification in Barrett esophagus surveillance: A multicenter case-control study. Medicine (Baltimore). 95:e54022016. View Article : Google Scholar
26	Cooper WA, Kohonen-Corish MR, McCaughan B, Kennedy C, Sutherland RL and Lee CS: Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer. Histopathology. 55:28–36. 2009. View Article : Google Scholar : PubMed/NCBI
27	Nozoe T, Inutsuka S, Honda M, Ezaki T and Korenaga D: Clinicopathologic significance of cyclin A expression in colorectal carcinoma. J Exp Clin Cancer Res. 23:127–133. 2004.PubMed/NCBI
28	Gopinathan L, Tan SL, Padmakumar VC, Coppola V, Tessarollo L and Kaldis P: Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis. Cancer Res. 74:3870–3879. 2014. View Article : Google Scholar : PubMed/NCBI
29	Srethapakdi M, Liu F, Tavorath R and Rosen N: Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res. 60:3940–3946. 2000.PubMed/NCBI
30	Xu J, e C, Yao Y, Ren S, Wang G and Jin H: Matrix metalloproteinase expression and molecular interaction network analysis in gastric cancer. Oncol Lett. 12:2403–2408. 2016. View Article : Google Scholar : PubMed/NCBI
31	Klupp F, Neumann L, Kahlert C, Diers J, Halama N, Franz C, Schmidt T, Koch M, Weitz J, Schneider M, et al: Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients. BMC Cancer. 16:4942016. View Article : Google Scholar : PubMed/NCBI
32	Zhu R and Tian Y: Astrocyte elevated gene-1 increases invasiveness of NSCLC through up-regulating MMP7. Cell Physiol Biochem. 37:1187–1195. 2015. View Article : Google Scholar : PubMed/NCBI
33	Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V, Mármol M, Gallardo E, Maria Augé J, Longarón R, et al: Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer. 121:1066–1071. 2007. View Article : Google Scholar : PubMed/NCBI
34	Niedworok C, Tschirdewahn S, Reis H, Lehmann N, Szucs M, Nyirady P, Romics I, Rubben H and Szarvas T: serum chromogranin a as a complementary marker for the prediction of prostate cancer-specific survival. Pathol Oncol Res. 23:643–650. 2017. View Article : Google Scholar
35	Zhang Q, Liu S, Parajuli KR, Zhang W, Zhang K, Mo Z, Liu J, Chen Z, Yang S, Wang AR, et al: Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition. Oncogene. 36:687–699. 2017. View Article : Google Scholar :
36	Zhao L, Wang W, Xu L, Yi T, Zhao X, Wei Y, Vermeulen L, Goel A, Zhou S and Wang X: Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer. Oncogene. 38:2305–2319. 2019. View Article : Google Scholar :
37	Li HP, Ji JF, Hou KY, Lei YT, Zhao HM, Wang J, Zheng J, Liu JY, Wang MP, Xiao Y, et al: Prediction of recurrence risk in early breast cancer using human epidermal growth factor 2 and cyclin A2. Chin Med J (Engl). 123:431–437. 2010.